Evidence map›Paper›PMID 30576432›Full record

Observational studyCardiovascular research2019

Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study.

Peter Penson, D Leann Long, George Howard, Virginia J Howard, Steven R Jones, Seth S Martin, Dimitri P Mikhailidis, Paul Muntner, Manfredi Rizzo, Daniel J Rader and 4 more

Open access · bronzeAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Cardiovascular research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. HDL Function across the Lifespan: From Childhood, to Pregnancy, to Old Age.International journal of molecular sciences · 2023
    Review
  11. Effects of Obesity and Calorie Restriction on Cancer Development.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. The role of statins in lung cancer.Archives of medical science : AMS · 2022
    Article
  17. Article
  18. Article
  19. RNA Silencing in the Management of Dyslipidemias.Current atherosclerosis reports · 2021
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 6 countries.

Peter PensonSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
D Leann LongDepartment of Biostatistics, UAB School of Public Health, Birmingham, AL, USA.
George HowardDepartment of Biostatistics, UAB School of Public Health, Birmingham, AL, USA.
Virginia J HowardDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Steven R JonesThe Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
Seth S MartinThe Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
Dimitri P MikhailidisDepartment of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK.
Paul MuntnerDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Manfredi RizzoBiomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Daniel J RaderDepartment of Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.
Monika M SaffordDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Amirhossein SahebkarBiotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Peter P TothThe Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
Maciej BanachDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland.
Johns Hopkins Medicine · USAlabama Department of Public Health · USUniversity of Alabama at Birmingham · USBiotechnology Research Center · IRCornell University · USIstituto Euro Mediterraneo di Scienza e Tecnologia · ITLiverpool John Moores University · GBMedical University of Lodz · PLUniversity College London · GBUniversity of Pennsylvania · US

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
REGARDS - MI StudyR01HL080477 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVITAN, EMILY B, SAFFORD, MONIKA M · 2006 to 2020
$11.6M
REasons for Geographic And Racial Differences in Stroke-Myocardial Infarction-4 (REGARDS-MI-4)R01HL165452 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVITAN, EMILY B, SAFFORD, MONIKA M · 2022 to 2025
$8.3M
NHLBI NIH HHS R01 HL080477NHLBI NIH HHS R01 HL165452NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

Aims: Relatively little is known about the health outcomes associated with very low plasma concentrations of high-density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We, therefore, investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study. Methods and results: Analysis was based on 21 751 participants from the REGARDS study who were free of CHD, other cardiovascular disease, and cancer at baseline and were categorized by baseline HDL-C into <30 mg/dL (very low), 30-<40 mg/dL (low), and ≥40 mg/dL (reference). A series of incremental Cox proportional hazards models were employed to assess the association between the HDL-C categories and outcomes. Statistical analysis was performed using both complete case methods and multiple imputations with chained equations. After adjustment for age, race, and sex, the hazard ratios (HRs) comparing the lowest and highest HDL-C categories were 1.48 [95% confidence interval (CI) 1.28-1.73] for all-cause mortality, 1.35 (95% CI 1.03-1.77) for cancer-specific mortality and 1.39 (95% CI 0.99-1.96) for incident CHD. These associations became non-significant in models adjusting for demographics, cardiovascular risk factors, and treatment for dyslipidaemia. We found evidence for an HDL paradox, whereby low HDL (30-<40 mg/dL) was associated with reduced risk of incident CHD in black participants in a fully adjusted complete case model (HR 0.63; 95% CI 0.46-0.88) and after multiple imputation analyses (HR 0.76; 95% CI 0.58-0.98). HDL-C (<30 mg/dL) was significantly associated with poorer outcomes in women for all outcomes, especially with respect to cancer mortality (HR 2.31; 95% CI 1.28-4.16) in a fully adjusted complete case model, replicated using multiple imputation (HR 1.81; 95% CI 1.03-3.20). Conclusion: Low HDL-C was associated with reduced risk of incident CHD in black participants suggesting a potential HDL paradox for incident CHD. Very low HDL-C in women was significantly associated with cancer mortality in a fully adjusted complete case model.

Indexed as

Health Status DisparitiesAgedBiomarkersBlack or African AmericanCause of DeathCholesterol, HDLCoronary DiseaseDown-RegulationDyslipidemiasFemaleHumansIncidenceLongitudinal StudiesMaleMiddle AgedNeoplasmsBiomarkersCholesterol, HDL

Identifiers

PMID30576432
PMCPMC6302258
OpenAlexW2887296216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.